PMID- 34475994
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220218
IS  - 1837-9664 (Print)
IS  - 1837-9664 (Electronic)
IS  - 1837-9664 (Linking)
VI  - 12
IP  - 19
DP  - 2021
TI  - Identification of a prognostic 4-mRNA signature in laryngeal squamous cell 
      carcinoma.
PG  - 5807-5816
LID - 10.7150/jca.47557 [doi]
AB  - Background: Laryngeal squamous cell carcinoma (LSCC) is one of the most common 
      malignancy in the respiratory tract and could reduce the quality of life 
      seriously like dyspnea, dysphonia and dysphagia. Moreover, 5-year survival rate 
      has decreased over the past 40 years. This study was designed to identify mRNAs 
      that related to prognosis in LSCC to enable early detection and outcome 
      improvement. Methods: Gene expression profiles from Gene Expression Omnibus (GEO) 
      (GSE59102, GSE84957) and The Cancer Genome Atlas (TCGA) were analyzed to identify 
      differentially expressed genes (DEGs) with the help of bioinformatics tools. 
      Functional enrichment analyses including Gene Ontology (GO) and pathway analysis 
      were carried out to investigate the role of those genes and underlying molecular 
      mechanisms in LSCC. Cox's regression analyses (univariate, LASSO and multivariate 
      in order) were utilized to identify DEGs related with patients' overall survival 
      and a 4-mRNA-based prognostic risk score model was established. Univariate and 
      multivariate Cox's regression analyses were then performed on LSCC data (90 
      patients left) to identify independent predictors of OS, including the signature 
      and clinicopathologic variables. The prognostic value of the gene signature was 
      further validated and the genes were analyzed by GEPIA to get pan-cancer 
      expression profiles. Results: 444 differentially expressed mRNAs (250 
      up-regulated, 194 down-regulated) were identified based on the threshold of fold 
      change > 2 and adjusted p value < 0.05. Univariate Cox's regression analysis 
      showed that high risk score (HR: 3.056, 95% confidence interval [CI]: 
      0.135-0.649, p<0.001) and female (HR: 0.296, 95% CI: 2.020-4.624, p=0.002) were 
      associated with relatively poor prognosis. Further multivariate Cox's regression 
      analysis indicated that risk score and gender were independent prognostic factors 
      (p<0.05). The risk score model could stratify patients into high- and low‑risk 
      groups, which presents significantly differential overall survival (p= 
      8.252e-04). The AUCs of 1-, 3- and 5-year OS were 0.724, 0.783 and 0.818, 
      respectively. Conclusions: Our study provides evidence that the four-mRNA 
      signature could serve as a biomarker to predict prognosis in LSCC, especially in 
      long-term.
CI  - (c) The author(s).
FAU - Zhang, Cheng
AU  - Zhang C
AD  - Department of Otorhinolaryngology-head and neck surgery, Shanghai General 
      Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FAU - Shen, Bin
AU  - Shen B
AD  - Department of Otorhinolaryngology-head and neck surgery, Shanghai General 
      Hospital, Shanghai, China.
FAU - Chen, Xinwei
AU  - Chen X
AD  - Department of Otorhinolaryngology-head and neck surgery, Shanghai General 
      Hospital, Shanghai, China.
FAU - Gao, Shang
AU  - Gao S
AD  - Department of Otorhinolaryngology-head and neck surgery, Shanghai General 
      Hospital, Shanghai, China.
FAU - Ying, Xinjiang
AU  - Ying X
AD  - Department of Otorhinolaryngology-head and neck surgery, Shanghai General 
      Hospital, Shanghai, China.
FAU - Dong, Pin
AU  - Dong P
AD  - Department of Otorhinolaryngology-head and neck surgery, Shanghai General 
      Hospital, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20210803
PL  - Australia
TA  - J Cancer
JT  - Journal of Cancer
JID - 101535920
PMC - PMC8408111
OTO - NOTNLM
OT  - GEO
OT  - Laryngeal squamous cell carcinoma
OT  - TCGA
OT  - prognosis
OT  - risk model
COIS- Competing Interests: The authors have declared that no competing interest exists.
EDAT- 2021/09/04 06:00
MHDA- 2021/09/04 06:01
PMCR- 2021/01/01
CRDT- 2021/09/03 06:49
PHST- 2020/04/29 00:00 [received]
PHST- 2021/07/18 00:00 [accepted]
PHST- 2021/09/03 06:49 [entrez]
PHST- 2021/09/04 06:00 [pubmed]
PHST- 2021/09/04 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - jcav12p5807 [pii]
AID - 10.7150/jca.47557 [doi]
PST - epublish
SO  - J Cancer. 2021 Aug 3;12(19):5807-5816. doi: 10.7150/jca.47557. eCollection 2021.